Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.77 CHF | +1.71% | +3.12% | +21.10% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.10% | 15.64B | |
+19.42% | 43.78B | |
+18.87% | 21.56B | |
+25.15% | 15.25B | |
+55.77% | 13.02B | |
-0.05% | 6.79B | |
-15.94% | 6.36B | |
+19.77% | 5.81B | |
-8.87% | 5.73B | |
+27.27% | 4.72B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars